Trevi Therapeutics, Inc. Number of Reportable Segments
Trevi Therapeutics, Inc. (TRVI) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-06
- Trevi Therapeutics, Inc. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Trevi Therapeutics, Inc. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Trevi Therapeutics, Inc. number of reportable segments for the quarter ending 2024-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Trevi Therapeutics, Inc. number of reportable segments for the quarter ending 2023-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Trevi Therapeutics, Inc. number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- Trevi Therapeutics, Inc. number of reportable segments for fiscal 2024 was 1.00 Segment, a 0.00% change from fiscal 2023.
- Trevi Therapeutics, Inc. number of reportable segments for fiscal 2023 was 1.00 Segment, a 0.00% change from fiscal 2022.
- Trevi Therapeutics, Inc. number of reportable segments for fiscal 2022 was 1.00 Segment, a 0.00% change from fiscal 2021.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-17 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-18 | |||
| 2024-09-30 | 1.00 Segment 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | 1.00 Segment 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | 1.00 Segment 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-03-20 | |||
| 2023-09-30 | 1.00 Segment 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 1.00 Segment 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 1.00 Segment 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | 1.00 Segment 10-K · filed 2023-03-16 | |||
| 2022-09-30 | 1.00 Segment 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 1.00 Segment 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 1.00 Segment 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-03-17 | |||
| 2020-12-31 | 1.00 Segment 10-K · filed 2021-03-25 | |||
| 2019-12-31 | 1.00 Segment 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |